Hep Fall 2017 - Special Issue
Hep Fall 2017 - Special Issue
In every issue of Hep, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Profile
Stopping the Syndemic
Meet Lynn Taylor, MD, a primary care physician fighting for cures on the front lines of America’s opioid and hepatitis C crises.
From The Editor
Getting Better
Health officials say opioid and heroin addiction—along with the resulting overdoses and HCV transmission—is rising at an alarming rate.
News
Hepatitis C Treatment for Teens and Children
The FDA has expanded approval of the direct-acting antiviral treatments Sovaldi and Harvoni for adolescents ages 12 and older.
San Francisco Completes First Estimate of Hep C Epidemic
Nearly 13,000 San Francisco residents are currently living with hepatitis C virus (HCV).
WHO Adds New Hep C Med to Essential Medicines List
The World Health Organization (WHO) has added a new hepatitis C treatment to its updated 2017 Essential Medicines List.
Can Coffee Help Prevent Liver Disease?
If you’re a diehard coffee lover, here’s another reason to indulge.
Treatment News
No Benefit From Curing Hep C? Au Contraire!
Curing the hepatitis C virus (HCV) does not prolong life or reduce rates of HCV-related illness.
Cure Hep C, Leave Liver Transplant List?
For people with HCV who are on the liver transplant list because of severe liver damage, curing the virus may allow them to leave the list.
FDA OKs Gilead’s Vosevi as Round Two Treatment
It approved 12 weeks of Gilead Sciences’ Vosevi for the re-treatment of adults with all genotypes of HCV who do not have cirrhorsis.
FDA OKs AbbVie’s Mavyret for All Genotypes
The Food and Drug Administration has approved AbbVie’s once-daily Mavyret to treat all six major genotypes of hepatitis C virus (HCV).
